Pulmonary vascular changes in asthma and COPD

Pulmonary Pharmacology and Therapeutics

Volumn 29, Issue 2, 2014, Pages 144-155

  Harkness, Louise M ^a   Kanabar, Varsha ^b   Sharma, Hari S ^c   Westergren Thorsson, Gunilla ^d   Larsson Callerfelt, Anna Karin ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Airway smooth muscle; Angiogenesis; Asthma; COPD; Pulmonary fibroblast; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIN; AZITHROMYCIN; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GLUCOCORTICOID; MACROLIDE; MICRORNA 20B; PHOSPHODIESTERASE INHIBITOR; THROMBOXANE; VASCULOTROPIN;

ARTICLE; ASTHMA; BLOOD VESSEL PERMEABILITY; BRONCHIAL ARTERY; CHRONIC OBSTRUCTIVE LUNG DISEASE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG BLOOD VESSEL; LUNG CIRCULATION; PERICYTE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; ANIMAL; LUNG; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR REMODELING; VASCULARIZATION;

ANIMALS; ASTHMA; HUMANS; LUNG; PULMONARY CIRCULATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VASCULAR REMODELING;

EID: 84922580405     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.09.003     Document Type: Article

References (147)

1. Postma D.S., Timens W. Remodeling in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:434-439.
2. Zanini A., Chetta A., Imperatori A.S., Spanevello A., Olivieri D. The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respir Res 2010, 11:132.
3. Siafakas N.M., Antoniou K.M., Tzortzaki E.G. Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007, 2:453-462.
4. Dunnill M.S. The pathology of asthma, with special reference to changes in the bronchial mucosa. JClin Pathol 1960, 13:27-33.
5. Li X., Wilson J.W. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit care Med 1997, 156:229-233.
6. Kuwano K., Bosken C.H., Pare P.D., Bai T.R., Wiggs B.R., Hogg J.C. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993, 148:1220-1225.
7. Hashimoto M., Tanaka H., Abe S. Quantitative analysis of bronchial wall vascularity in the medium and small airways of patients with asthma and COPD. Chest 2005, 127:965-972.
8. McDonald D.M. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001, 164:S39-S45.
9. Doherty T., Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 2007, 19:676-680.
10. Kranenburg A.R., De Boer W.I., Van Krieken J.H., Mooi W.J., Walters J.E., Saxena P.R., et al. Enhanced expression of fibroblast growth factors and receptor fgfr-1 during vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002, 27:517-525.
11. Kranenburg A.R., de Boer W.I., Alagappan V.K., Sterk P.J., Sharma H.S. Enhanced bronchial expression of vascular endothelial growth factor and receptors (flk-1 and flt-1) in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:106-113.
12. Alagappan V.K., de Boer W.I., Misra V.K., Mooi W.J., Sharma H.S. Angiogenesis and vascular remodeling in chronic airway diseases. Cell Biochem Biophys 2013, 67:219-234.
13. Santos S., Peinado V.I., Ramirez J., Melgosa T., Roca J., Rodriguez-Roisin R., et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002, 19:632-638.
14. Chaouat A., Naeije R., Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008, 32:1371-1385.
15. Hislop A.A. Airway and blood vessel interaction during lung development. JAnat 2002, 201:325-334.
16. Mitzner W., Wagner E.M. Vascular remodeling in the circulations of the lung. JAppl Physiol 1985, 2004(97):1999-2004.
17. Wilson J.W., Kotsimbos T. Airway vascular remodeling in asthma. Curr Allergy Asthma Rep 2003, 3:153-158.
18. Paredi P., Barnes P.J. The airway vasculature: recent advances and clinical implications. Thorax 2009, 64:444-450.
19. Ribatti D., Nico B., Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol 2011, 55:261-268.
20. Di Wang H., Ratsep M.T., Chapman A., Boyd R. Adventitial fibroblasts in vascular structure and function: the role of oxidative stress and beyond. Can J Physiol Pharmacol 2010, 88:177-186.
21. Carroll N.G., Cooke C., James A.L. Bronchial blood vessel dimensions in asthma. Am J Respir Crit Care Med 1997, 155:689-695.
22. Dunnill M.S., Massarella G.R., Anderson J.A. Acomparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema. Thorax 1969, 24:176-179.
23. Charan N.B., Baile E.M., Pare P.D. Bronchial vascular congestion and angiogenesis. Eur Respir J 1997, 10:1173-1180.
24. Wilson J.W., Hii S. The importance of the airway microvasculature in asthma. Curr Opin Allergy Clin Immunol 2006, 6:51-55.
25. Bai T.R., Knight D.A. Structural changes in the airways in asthma: observations and consequences. Clin Sci (Lond) 2005, 108:463-477.
26. Simcock D.E., Kanabar V., Clarke G.W., Mahn K., Karner C., O'Connor B.J., et al. Induction of angiogenesis by airway smooth muscle from patients with asthma. Am J Respir Crit Care Med 2008, 178:460-468.
27. Alagappan V.K., McKay S., Widyastuti A., Garrelds I.M., Bogers A.J., Hoogsteden H.C., et al. Proinflammatory cytokines upregulate mRNA expression and secretion of vascular endothelial growth factor in cultured human airway smooth muscle cells. Cell Biochem Biophys 2005, 43:119-129.
28. Alagappan V.K., Willems-Widyastuti A., Seynhaeve A.L., Garrelds I.M., ten Hagen T.L., Saxena P.R., et al. Vasoactive peptides upregulate mRNA expression and secretion of vascular endothelial growth factor in human airway smooth muscle cells. Cell Biochem Biophys 2007, 47:109-118.
29. McKay S., Hirst S.J., Haas M.B., de Jongste J.C., Hoogsteden H.C., Saxena P.R., et al. Tumor necrosis factor-alpha enhances mRNA expression and secretion of interleukin-6 in cultured human airway smooth muscle cells. Am J Respir Cell Mol Biol 2000, 23:103-111.
30. Ribatti D., Puxeddu I., Crivellato E., Nico B., Vacca A., Levi-Schaffer F. Angiogenesis in asthma. Clin Exp Allergy 2009, 39:1815-1821.
31. Lee Y.C., Kwak Y.G., Song C.H. Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. JImmunol 2002, 168:3595-3600.
32. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395.
33. Andersson-Sjoland A., Thiman L., Nihlberg K., Hallgren O., Rolandsson S., Skog I., et al. Fibroblast phenotypes and their activity are changed in the wound healing process after lung transplantation. JHeart Lung Transpl 2011, 30:945-954.
34. Greenberg J.I., Shields D.J., Barillas S.G., Acevedo L.M., Murphy E., Huang J., et al. Arole for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
35. Zanini A., Chetta A., Olivieri D. Therapeutic perspectives in bronchial vascular remodeling in COPD. Ther Adv Respir Dis 2008, 2:179-187.
36. Zeidan A., Nordstrom I., Albinsson S., Malmqvist U., Sward K., Hellstrand P. Stretch-induced contractile differentiation of vascular smooth muscle: sensitivity to actin polymerization inhibitors. Am J Physiol Cell Physiol 2003, 284:C1387-C1396.
37. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84:767-801.
38. Davis-Dusenbery B.N., Wu C., Hata A. Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol 2011, 31:2370-2377.
39. Joshi S.R., McLendon J.M., Comer B.S., Gerthoffer W.T. Micrornas-control of essential genes: implications for pulmonary vascular disease. Pulm Circ 2011, 1:357-364.
40. Wagner E.M., Mitzner W.A. Effect of hypoxia on bronchial circulation. JAppl Physiol 1985, 1988(65):1627-1633.
41. Peinado V.I., Barbera J.A., Abate P., Ramirez J., Roca J., Santos S., et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit care Med 1999, 159:1605-1611.
42. Diez M., Barbera J.A., Ferrer E., Fernandez-Lloris R., Pizarro S., Roca J., et al. Plasticity of cd133+ cells: role in pulmonary vascular remodeling. Cardiovasc Res 2007, 76:517-527.
43. Frid M.G., Kale V.A., Stenmark K.R. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: invitro analysis. Circ Res 2002, 90:1189-1196.
44. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
45. Burgess J.K., Boustany S., Moir L.M., Weckmann M., Lau J.Y., Grafton K., et al. Reduction of tumstatin in asthmatic airways contributes to angiogenesis, inflammation, and hyperresponsiveness. Am J Respir Crit care Med 2010, 181:106-115.
46. Simcock D.E., Kanabar V., Clarke G.W., O'Connor B.J., Lee T.H., Hirst S.J. Proangiogenic activity in bronchoalveolar lavage fluid from patients with asthma. Am J Respir Crit Care Med 2007, 176:146-153.
47. Chetta A., Zanini A., Foresi A., D'Ippolito R., Tipa A., Castagnaro A., et al. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin Exp Allergy 2005, 35:1437-1442.
48. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
49. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
50. Hoshino M., Takahashi M., Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. JAllergy Clin Immunol 2001, 107:295-301.
51. Kamio K., Sato T., Liu X., Sugiura H., Togo S., Kobayashi T., et al. Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture. Am J Physiol Lung Cell Mol Physiol 2008, 294:L1226-L1232.
52. Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004, 93:39-43.
53. Wen F.Q., Liu X., Manda W., Terasaki Y., Kobayashi T., Abe S., et al. TH2 cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. JAllergy Clin Immunol 2003, 111:1307-1318.
54. Hoshino M., Nakamura Y., Hamid Q.A. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. JAllergy Clin Immunol 2001, 107:1034-1038.
55. Sharma H.S., Alagappan V.K., Willems-Widyastuti A., Mooi W.J., de Boer W.I. Nitric oxide donors augment interleukin-1beta-induced vascular endothelial growth factor in airway smooth muscle cells. Cell Biochem Biophys 2013, 67:247-254.
56. Willems-Widyastuti A., Alagappan V.K., Arulmani U., Vanaudenaerde B.M., de Boer W.I., Mooi W.J., et al. Transforming growth factor-beta 1 induces angiogenesis invitro via vegf production in human airway smooth muscle cells. Indian J Biochem Biophys 2011, 48:262-269.
57. Dempsey E.C., Cool C.D., Littler C.M. Lung disease and PKCs. Pharmacol Res 2007, 55:545-559.
58. Jones C.P., Rankin S.M. Bone marrow-derived stem cells and respiratory disease. Chest 2011, 140:205-211.
59. Rafat N., Hanusch C., Brinkkoetter P.T., Schulte J., Brade J., Zijlstra J.G., et al. Increased circulating endothelial progenitor cells in septic patients: correlation with survival. Crit Care Med 2007, 35:1677-1684.
60. Asosingh K., Swaidani S., Aronica M., Erzurum S.C. TH1- and TH2-dependent endothelial progenitor cell recruitment and angiogenic switch in asthma. JImmunol 2007, 178:6482-6494.
61. Jones C.P., Pitchford S.C., Lloyd C.M., Rankin S.M. CXCR2 mediates the recruitment of endothelial progenitor cells during allergic airways remodeling. Stem Cells 2009, 27:3074-3081.
62. Sala E., Villena C., Balaguer C., Rios A., Fernandez-Palomeque C., Cosio B.G., et al. Abnormal levels of circulating endothelial progenitor cells during exacerbations of COPD. Lung 2010, 188:331-338.
63. Mehrad B., Burdick M.D., Zisman D.A., Keane M.P., Belperio J.A., Strieter R.M. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007, 353:104-108.
64. Moeller A., Gilpin S.E., Ask K., Cox G., Cook D., Gauldie J., et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179:588-594.
65. Bucala R., Spiegel L.A., Chesney J., Hogan M., Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994, 1:71-81.
66. Chesney J., Metz C., Stavitsky A.B., Bacher M., Bucala R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. JImmunol 1998, 160:419-425.
67. Hu D.E., Hori Y., Fan T.P. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993, 17:135-143.
68. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801.
69. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56:549-580.
70. Nihlberg K., Larsen K., Hultgardh-Nilsson A., Malmstrom A., Bjermer L., Westergren-Thorsson G. Tissue fibrocytes in patients with mild asthma: a possible link to thickness of reticular basement membrane?. Respir Res 2006, 7:50.
71. Wang C.H., Huang C.D., Lin H.C., Lee K.Y., Lin S.M., Liu C.Y., et al. Increased circulating fibrocytes in asthma with chronic airflow obstruction. Am J Respir Crit care Med 2008, 178:583-591.
72. Schmidt M., Sun G., Stacey M.A., Mori L., Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. JImmunol 2003, 171:380-389.
73. Yeager M.E., Frid M.G., Stenmark K.R. Progenitor cells in pulmonary vascular remodeling. Pulm Circ 2011, 1:3-16.
74. Peinado V.I., Ramirez J., Roca J., Rodriguez-Roisin R., Barbera J.A. Identification of vascular progenitor cells in pulmonary arteries of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2006, 34:257-263.
75. Barbera J.A., Peinado V.I. Vascular progenitor cells in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2011, 8:528-534.
76. Benayoun L., Druilhe A., Dombret M.C., Aubier M., Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003, 167:1360-1368.
77. Kumar S.D., Emery M.J., Atkins N.D., Danta I., Wanner A. Airway mucosal blood flow in bronchial asthma. Am J Respir Crit Care Med 1998, 158:153-156.
78. Vrugt B., Wilson S., Bron A., Holgate S.T., Djukanovic R., Aalbers R. Bronchial angiogenesis in severe glucocorticoid-dependent asthma. Eur Respir J 2000, 15:1014-1021.
79. Chetta A., Zanini A., Olivieri D. Therapeutic approach to vascular remodelling in asthma. Pulm Pharmacol Ther 2007, 20:1-8.
80. Detoraki A., Granata F., Staibano S., Rossi F.W., Marone G., Genovese A. Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy 2010, 65:946-958.
81. Khor Y.H., Teoh A.K., Lam S.M., Mo D.C., Weston S., Reid D.W., et al. Increased vascular permeability precedes cellular inflammation as asthma control deteriorates. Clin Exp Allergy 2009, 39:1659-1667.
82. Salvato G. Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-asthmatic subjects. Thorax 2001, 56:902-906.
83. Orsida B.E., Li X., Hickey B., Thien F., Wilson J.W., Walters E.H. Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 1999, 54:289-295.
84. Van der Velden J., Barker D., Barcham G., Koumoundouros E., Snibson K. Increased vascular density is a persistent feature of airway remodeling in a sheep model of chronic asthma. Exp Lung Res 2012, 38:307-315.
85. Rydell-Tormanen K., Johnson J.R., Fattouh R., Jordana M., Erjefalt J.S. Induction of vascular remodeling in the lung by chronic house dust mite exposure. Am J Respir Cell Mol Biol 2008, 39:61-67.
86. Bischof R.J., Snibson K., Shaw R., Meeusen E.N. Induction of allergic inflammation in the lungs of sensitized sheep after local challenge with house dust mite. Clin Exp Allergy 2003, 33:367-375.
87. Snibson K.J., Bischof R.J., Slocombe R.F., Meeusen E.N. Airway remodelling and inflammation in sheep lungs after chronic airway challenge with house dust mite. Clin Exp Allergy 2005, 35:146-152.
88. Neve A., Cantatore F.P., Maruotti N., Corrado A., Ribatti D. Extracellular matrix modulates angiogenesis in physiological and pathological conditions. Biomed Res Int 2014, 2014:756078.
89. Kristan S.S., Malovrh M.M., Silar M., Kern I., Flezar M., Kosnik M., et al. Airway angiogenesis in patients with rhinitis and controlled asthma. Clin Exp Allergy 2009, 39:354-360.
90. McCullagh A., Rosenthal M., Wanner A., Hurtado A., Padley S., Bush A. The bronchial circulation-worth a closer look: a review of the relationship between the bronchial vasculature and airway inflammation. Pediatr Pulmonol 2010, 45:1-13.
91. Meyer N., Christoph J., Makrinioti H., Indermitte P., Rhyner C., Soyka M., et al. Inhibition of angiogenesis by IL-32: possible role in asthma. JAllergy Clin Immunol 2012, 129:964-973. e967.
92. Lee C.G., Link H., Baluk P., Homer R.J., Chapoval S., Bhandari V., et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004, 10:1095-1103.
93. Song C., Ma H., Yao C., Tao X., Gan H. Alveolar macrophage-derived vascular endothelial growth factor contributes to allergic airway inflammation in a mouse asthma model. Scand J Immunol 2012, 75:599-605.
94. Sharma S., Murphy A.J., Soto-Quiros M.E., Avila L., Klanderman B.J., Sylvia J.S., et al. Association of VEGF polymorphisms with childhood asthma, lung function and airway responsiveness. Eur Respir J 2009, 33:1287-1294.
95. Kreiner-Moller E., Chawes B.L., Vissing N.H., Koppelman G.H., Postma D.S., Madsen J.S., et al. VEGFA variants are associated with pre-school lung function, but not neonatal lung function. Clin Exp Allergy 2013, 43:1236-1245.
96. Vivodtzev I., Tamisier R., Baguet J.P., Borel J.C., Levy P., Pepin J.L. Arterial stiffness in COPD. Chest 2014, 145:861-875.
97. Donaldson G.C., Hurst J.R., Smith C.J., Hubbard R.B., Wedzicha J.A. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010, 137:1091-1097.
98. MacNee W., Tuder R.M. New paradigms in the pathogenesis of chronic obstructive pulmonary disease i. Proc Am Thorac Soc 2009, 6:527-531.
99. Noguera A., Batle S., Miralles C., Iglesias J., Busquets X., MacNee W., et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001, 56:432-437.
100. Russell R.E., Culpitt S.V., DeMatos C., Donnelly L., Smith M., Wiggins J., et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002, 26:602-609.
101. Capelli A., Di Stefano A., Gnemmi I., Balbo P., Cerutti C.G., Balbi B., et al. Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J 1999, 14:160-165.
102. Tufvesson E., Ekberg M., Bjermer L. Inflammatory biomarkers in sputum predict COPD exacerbations. Lung 2013, 191:413-416.
103. Tian W., Jiang X., Sung Y.K., Qian J., Yuan K., Nicolls M.R. Leukotrienes in pulmonary arterial hypertension. Immunol Res 2014, 58:387-393.
104. Gessler T., Seeger W., Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. JAerosol Med Pulm Drug Deliv 2008, 21:1-12.
105. Moncada S., Higgs E.A., Vane J.R. Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1977, 1:18-20.
106. Larsson-Callerfelt A.K., Hallgren O., Andersson-Sjoland A., Thiman L., Bjorklund J., Kron J., et al. Defective alterations in the collagen network to prostacyclin in COPD lung fibroblasts. Respir Res 2013, 14:21.
107. Hegewald M.J., Elliott C.G. Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 2009, 135:536-537.
108. Dernaika T.A., Beavin M., Kinasewitz G.T. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010, 79:377-382.
109. Stratton R., Shiwen X., Martini G., Holmes A., Leask A., Haberberger T., et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. JClin Invest 2001, 108:241-250.
110. Togo S., Holz O., Liu X., Sugiura H., Kamio K., Wang X., et al. Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am J Respir Crit care Med 2008, 178:248-260.
111. Wu G., Luo J., Rana J.S., Laham R., Sellke F.W., Li J. Involvement of COX-2 in VEGF-induced angiogenesis via p38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 2006, 69:512-519.
112. Cruz-Gervis R., Stecenko A.A., Dworski R., Lane K.B., Loyd J.E., Pierson R., et al. Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis. Respir Res 2002, 3:17.
113. Moncada S., Gryglewski R., Bunting S., Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976, 263:663-665.
114. Chakraborty R., Pydi S.P., Gleim S., Bhullar R.P., Hwa J., Dakshinamurti S., et al. New insights into structural determinants for prostanoid thromboxane a2 receptor- and prostacyclin receptor-g protein coupling. Mol Cell Biol 2013, 33:184-193.
115. Coleman R.A., Smith W.L., Narumiya S. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994, 46:205-229.
116. Larsson A.K., Hagfjard A., Dahlen S.E., Adner M. Prostaglandin d(2) induces contractions through activation of tp receptors in peripheral lung tissue from the guinea pig. Eur J Pharmacol 2011, 669:136-142.
117. Davi G., Basili S., Vieri M., Cipollone F., Santarone S., Alessandri C., et al. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The chronic obstructive bronchitis and haemostasis study group. Am J Respir Crit care Med 1997, 156:1794-1799.
118. Fimognari F.L., Scarlata S., Conte M.E., Incalzi R.A. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008, 3:89-96.
119. Zanini A., Chetta A., Saetta M., Baraldo S., Castagnetti C., Nicolini G., et al. Bronchial vascular remodelling in patients with COPD and its relationship with inhaled steroid treatment. Thorax 2009, 64:1019-1024.
120. Sabit R., Bolton C.E., Edwards P.H., Pettit R.J., Evans W.D., McEniery C.M., et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit care Med 2007, 175:1259-1265.
121. Maclay J.D., McAllister D.A., Mills N.L., Paterson F.P., Ludlam C.A., Drost E.M., et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit care Med 2009, 180:513-520.
122. Mills N.L., Miller J.J., Anand A., Robinson S.D., Frazer G.A., Anderson D., et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008, 63:306-311.
123. Stenmark K.R., Fagan K.A., Frid M.G. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006, 99:675-691.
124. Papaioannou A.I., Kostikas K., Kollia P., Gourgoulianis K.I. Clinical implications for vascular endothelial growth factor in the lung: friend or foe?. Respir Res 2006, 7:128.
125. Bailey S.R., Boustany S., Burgess J.K., Hirst S.J., Sharma H.S., Simcock D.E., et al. Airway vascular reactivity and vascularisation in human chronic airway disease. Pulm Pharmacol Ther 2009, 22:417-425.
126. Kanazawa H., Asai K., Hirata K., Yoshikawa J. Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med 2003, 114:354-358.
127. Santos S., Peinado V.I., Ramirez J., Morales-Blanhir J., Bastos R., Roca J., et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:1250-1256.
128. Valipour A., Schreder M., Wolzt M., Saliba S., Kapiotis S., Eickhoff P., et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008, 115:225-232.
129. Olivieri D., Chetta A. Therapeutic perspectives in vascular remodeling in asthma and chronic obstructive pulmonary disease. Chem Immunol Allergy 2014, 99:216-225.
130. Stempel D.A., Riedel A.A., Carranza Rosenzweig J.R. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. Curr Med Res Opin 2006, 22:463-470.
131. Delea T.E., Hagiwara M., Stanford R.H., Stempel D.A. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clin Ther 2008, 30:560-571.
132. Yao H., de Boer W.I., Rahman I. Targeting lung inflammation: novel therapies for the treatment of COPD. Curr Respir Med Rev 2008, 4:57-68.
133. Chetta A., Olivieri D. Role of inhaled steroids in vascular airway remodelling in asthma and COPD. Int J Endocrinol 2012, 2012:397693.
134. Barnes P.J. New therapies for asthma: Is there any progress?. Trends Pharmacol Sci 2010, 31:335-343.
135. Itkin I.H., Menzel M.L. The use of macrolide antibiotic substances in the treatment of asthma. JAllergy 1970, 45:146-162.
136. Gotfried M.H. Macrolides for the treatment of chronic sinusitis, asthma, and copd. Chest 2004, 125:52S-60S. quiz 60S-61S.
137. Crosbie P.A., Woodhead M.A. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009, 33:171-181.
138. Verleden G.M., Vanaudenaerde B.M., Dupont L.J., Van Raemdonck D.E. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit care Med 2006, 174:566-570.
139. Seemungal T.A., Wilkinson T.M., Hurst J.R., Perera W.R., Sapsford R.J., Wedzicha J.A. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit care Med 2008, 178:1139-1147.
140. Willems-Widyastuti A., Vanaudenaerde B.M., Vos R., Dilisen E., Verleden S.E., De Vleeschauwer S.I., et al. Azithromycin attenuates fibroblast growth factors induced vascular endothelial growth factor via p38(mapk) signaling in human airway smooth muscle cells. Cell Biochem Biophys 2013, 67:331-339.
141. Zhong H., Wu Y., Belardinelli L., Zeng D. A2b adenosine receptors induce il-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol 2006, 35:587-592.
142. Albert R.K., Connett J., Bailey W.C., Casaburi R., Cooper J.A., Criner G.J., et al. Azithromycin for prevention of exacerbations of COPD. NEngl J Med 2011, 365:689-698.
143. Netherton S.J., Maurice D.H. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: Implications in angiogenesis. Mol Pharmacol 2005, 67:263-272.
144. Maurice D.H., Ke H., Ahmad F., Wang Y., Chung J., Manganiello V.C. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014, 13:290-314.
145. Page C.P., Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 2012, 12:275-286.
146. Ikari J., Michalski J.M., Iwasawa S., Gunji Y., Nogel S., Park J.H., et al. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin e2. Am J Respir Cell Mol Biol 2013, 49:571-581.
147. Zhu B., Zhang L., Alexeyev M., Alvarez D.F., Strada S.J., Stevens T. Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype. Am J Physiol Lung Cell Mol Physiol 2009, 296:L220-L228.